The U.S. Food and Drug Administration granted accelerated approval to GlaxoSmithKline’s PD-1 checkpoint inhibitor Jemperli (dostarlimab) for a wider group of indications for adults with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer.

Europe’s drug regulator started a real-time review of the Covid-19 vaccine developed by French drugmaker Sanofi and Britain’s GlaxoSmithKline, the fifth shot currently under such a review as of July 20.

GlaxoSmithKline announced plans to build a massive campus for biotechnology and early-stage life science companies within the global healthcare company’s 92-acre research and development site in Stevenage, England.

GSK’s anemia drug for patients with kidney disease succeeded in late-stage trials, marking an important milestone for the British drugmaker as GlaxoSmithKline bolsters the company’s pipeline ahead of a split with its consumer healthcare venture.

Sanofi SA and GlaxoSmithKline Plc received an approval from Indian authorities for a late-stage clinical trial of their protein-based Covid-19 vaccine candidate, the drugmakers said on July 8.

A day after activist investor Elliott Management called on GlaxoSmithKline to sack Chief Executive Officer Emma Walmsley and line up new leadership for the pharma company when it splits into two entities, GSK’s board of directors soundly rejected the demand.

GlaxoSmithKline Plc and U.S. firm Alector Inc. will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on July 2.

Activist investor Elliott Management continues to push for a change in leadership at GlaxoSmithKline ahead of the planned 2022 split of the company.

Calling herself a “change agent,” GlaxoSmithKline Chief Executive Officer Emma Walmsley outlined plans to transform the pharmaceuticals business of GSK following the expected spin-off of the company’s consumer health division during an investor conference.

GlaxoSmithKline and Vir Biotechnology said final results from a late-stage study of their monoclonal antibody confirmed sotrovimab significantly reduced hospitalization and death among high-risk Covid-19 patients when given early in the disease.